Dauricine ( Dau ) significantly prolonged monophasic action potential duration of 50% and 90% repolarization ( MAPD50 and MAPD90 ) and functional refractory period (FRP)of the hearts in anesthetized cats in dose-dependent manner. At 9 mg/kg of Dau, MAPD50 was increased from 170?19 ms to 197?20 ms; MAPD90 from 216?16 ms to 249?18 ms; FRP from 177 ? 15 ms to 238 ? 20 ms.Dau 5 mg/kg iv followed by constant perfusion for 30 min could prevent the shortening of MAPD50 in the ischemic boundary area ( BA ) and increased FRP in the non-ischemic area ( NA ) , ischemic central area ( CA ) and BA, and markedly reduced the extent of dispersion of FRP of hearts in anesthetized cats. The results suggest that the antagonizing effect of Dau on the arrhythmias caused by acute myocardial ischemia and reperfusion might be related to its action of prolonging FRP and decreasing the dispersion of FRP in ischemic hearts.

Dauricine ( Dau ) was studied on the pharmacokinetics in experimental acute renal failure (ARF ) induced by HgCl2 or acute liver injury ( ALI ) induced by CC14 in rabbits.After iv administration of 5 mg/kg in normal rabbits the main pharmacokinetic parameters of Dau were as follows:t1/2=0.18?0.12 (h), t1/2?=3.18?0.95 ( h ) , Vd = 26.7l? 3.61 ( L/kg ) and Cl = 6.91 ? 1.74 ( L/h?kg-1 ). The pharmacokinetic parameters of Dau in ARF were not significantly different from that in normal. Cl (3.31?1.88 L/h?kg-1 ) in ALI was significantly lower than that in normal and t1/2? ( 8.85?4.57 h ) in ALI was considerably longer than that in normal.The results indicated that the pharmacokiaetics of Dau had no change in rabbits with ARF and its elimination was prolonged in rabbits with ALI.